ID   LNCaP C4-2B4
AC   CVCL_4787
SY   LNCaP-C4-2 B4; LNCaP-C42B4; C4-2B4; Sp 2816
DR   cancercelllines; CVCL_4787
DR   Wikidata; Q54902818
RX   PubMed=10881018;
WW   https://web.archive.org/web/20160703200703/http://capcelllines.ca:80/details.asp?id=165
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4784 ! LNCaP C4-2B
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=10881018; DOI=10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L;
RA   Thalmann G.N., Sikes R.A., Wu T.T., Degeorges A., Chang S.-M., Ozen M.,
RA   Pathak S., Chung L.W.K.;
RT   "LNCaP progression model of human prostate cancer: androgen-independence
RT   and osseous metastasis.";
RL   Prostate 44:91-103(2000).
//